Gilead Sciences (GILD) EPS (Basic) Growth (5y) (2014 - 2026)
Gilead Sciences (GILD) EPS (Basic) Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.69 Bn | 631.94 Bn | 17.26 Bn |
| 2 | AbbVie | 469.96 Bn | 463.39 Bn | 12.70 Bn |
| 3 | Merck | 375.18 Bn | 368.04 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.49 Bn | 252.59 Bn | 12.86 Bn |
| 6 | Amgen | 236.49 Bn | 222.50 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.14% |
| Mar 31, 2026 | 3.49% |
| Dec 31, 2025 | 10.59% |
| Sep 30, 2025 | 54.24% |
| Jun 30, 2025 | 20.97% |
| Mar 31, 2025 | -2.84% |
| Dec 31, 2024 | 20.96% |
| Sep 30, 2024 | 25.31% |
| Jun 30, 2024 | -2.59% |
| Mar 31, 2024 | -33.05% |
| Dec 31, 2023 | 28.04% |
| Sep 30, 2023 | 1.45% |
| Jun 30, 2023 | -9.91% |
| Mar 31, 2023 | -7.71% |
| Dec 31, 2022 | 19.75% |
| Sep 30, 2022 | -7.28% |
| Jun 30, 2022 | -17.39% |
| Mar 31, 2022 | -65.87% |
| Dec 31, 2021 | -33.57% |
| Sep 30, 2021 | -3.92% |